Asset Details
Do you wish to reserve the book?
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
Do you wish to request the book?
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
2019
Overview
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia.
CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.
In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a 18fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture.
CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.
•Well-ascertained cohort of 290 community-dwelling elderly individuals in Quebec.•Large number of individuals with subjective cognitive decline studied longitudinally.•Clinical, neuropsychology, neuroimaging, and biomaterials available for Alzheimer's disease studies.
Publisher
Elsevier Inc,Elsevier,Wiley
